Brought to you by 
Circle Pharma to work with Pfizer on two macrocyclic peptide programs
23 Sep 2014
Executive Summary
Concurrent with receiving undisclosed seed funding from Pfizer Inc. and QB3’s Mission Bay Capital, Circle Pharma Inc. (developing macrocyclic peptides) signed an agreement with the Big Pharma to develop cell permeable macrocyclic peptide therapeutics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Circle Pharma to work with Pfizer on two macrocyclic peptide programs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice